ICLR vs. INCY, MEDP, CRL, EXAS, IQV, WST, PHG, ZBH, CAH, and STE
Should you be buying ICON Public stock or one of its competitors? The main competitors of ICON Public include Incyte (INCY), Medpace (MEDP), Charles River Laboratories International (CRL), Exact Sciences (EXAS), IQVIA (IQV), West Pharmaceutical Services (WST), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Cardinal Health (CAH), and STERIS (STE). These companies are all part of the "medical" sector.
Incyte (NASDAQ:INCY) and ICON Public (NASDAQ:ICLR) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
Incyte received 615 more outperform votes than ICON Public when rated by MarketBeat users. Likewise, 73.63% of users gave Incyte an outperform vote while only 64.99% of users gave ICON Public an outperform vote.
97.0% of Incyte shares are held by institutional investors. Comparatively, 95.6% of ICON Public shares are held by institutional investors. 17.5% of Incyte shares are held by insiders. Comparatively, 44.0% of ICON Public shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Incyte presently has a consensus target price of $74.93, suggesting a potential upside of 31.23%. ICON Public has a consensus target price of $339.44, suggesting a potential upside of 7.86%. Given ICON Public's higher possible upside, research analysts plainly believe Incyte is more favorable than ICON Public.
ICON Public has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.
Incyte has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, ICON Public has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.
Incyte has a net margin of 19.78% compared to Incyte's net margin of 8.30%. ICON Public's return on equity of 12.83% beat Incyte's return on equity.
In the previous week, Incyte had 23 more articles in the media than ICON Public. MarketBeat recorded 23 mentions for Incyte and 0 mentions for ICON Public. ICON Public's average media sentiment score of 0.47 beat Incyte's score of 0.00 indicating that Incyte is being referred to more favorably in the media.
Summary
Incyte beats ICON Public on 10 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ICLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ICON Public Competitors List
Related Companies and Tools
